EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ethnopharmacology, phytochemistry, and pharmacology of Rubus parvifolius L (Máoméi): evidence and translational challenges

Boshi Duan, Chi Zhang, Xiao Hu, Xue Bai, Hu Peng, Han Zhao

Frontiers in Pharmacology · 03.08.2026 · 17

DOI: 10.3389/fphar.2026.1871424 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.08.2026. Verfasst von Boshi Duan und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Pek…. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rubus parvifolius L (Máoméi; Rosaceae) is a medicinal shrub widely used in southern Chinese folk medicine for haemorrhage, traumatic injury, inflammatory disorders, and certain cancers. Over the past 3 decades, increasing phytochemical and pharmacological investigation has expanded the preclinical literature for this species.

Objective

This review critically summarises the ethnomedicinal background, phytochemistry, pharmacology, extraction methodology, quality control, and toxicological evidence relating to R. parvifolius , while identifying key translational limitations and future research priorities.

Methods

Literature published between 1988 and May 2026 was retrieved from PubMed, Web of Science, CNKI, and SciFinder using “ Rubus parvifolius ” and its major Chinese synonyms (茅莓, 蛇泡簕, 三月泡) without language restriction.

Results

More than 60 individual metabolites have been identified across seven structural classes, with ursane- and oleanane-type pentacyclic triterpenoids and their saponins as the predominant pharmacologically investigated class. Preclinical studies—primarily of TSRP (total saponins of R. parvifolius ) — report anti-tumour, neuroprotective, hepatoprotective, anti-inflammatory, antibacterial, antioxidant, anti-fatigue, and anti-osteoclastogenic activities in cell-based and rodent models. Seven studies published during 2024–2025 have added substantially to this evidence base, contributing a four-tier botanical identification framework, an integrated UPLC-MS/MS plus network pharmacology characterisation of root metabolites, and the first reports of imatinib-resistance reversal and of ferroptosis-associated hepatic activity. A recent quantitative characterisation of leaf-flavonoid composition in an atopic dermatitis model and a GC-MS chemotaxonomic comparison across three Rubus species further refine the species-specific evidence base. The evidence remains predominantly preclinical, with mechanistic findings consisting largely of pathway-associated expression changes rather than experimentally validated mechanisms.

Conclusion

R. parvifolius possesses a pharmacologically diverse chemical profile with broad preclinical activity consistent with several traditional indications. Current evidence is preclinical and should be regarded as hypothesis-generating. Future priorities include pharmacokinetic studies, standardised extract characterisation, regulatory-grade toxicology, and clinically relevant oral-route validation.

Schlagwörter

Stichwörter der Autor:innen

Rubus parvifoliusethnopharmacologymáoméinigaichigoside F1phytochemistrysuavissimoside R1triterpenoid saponinsursolic acid

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Respiratory Medicine Department, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Ch…

Zitieren

APA

Duan, B., Zhang, C., Hu, X., Bai, X., Peng, H., & Zhao, H. (2026). Ethnopharmacology, phytochemistry, and pharmacology of Rubus parvifolius L (Máoméi): evidence and translational challenges. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1871424

Vancouver

Duan B, Zhang C, Hu X, Bai X, Peng H, Zhao H. Ethnopharmacology, phytochemistry, and pharmacology of Rubus parvifolius L (Máoméi): evidence and translational challenges. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1871424

BibTeX
@article{Duan2026,
  author = {Duan, Boshi and Zhang, Chi and Hu, Xiao and Bai, Xue and Peng, Hu and Zhao, Han},
  title = {Ethnopharmacology, phytochemistry, and pharmacology of Rubus parvifolius L (Máoméi): evidence and translational challenges},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1871424}
}
Kostenlos starten →